BiotechTube

suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin

Phase 3Terminated
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Macular Edema

Conditions

Macular Edema, Retinal Vein Occlusion

Trial Timeline

Mar 5, 2018 โ†’ Dec 18, 2018

NCT ID
NCT03203447

About suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin

suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin is a phase 3 stage product being developed by Clearside Biomedical for Macular Edema. The current trial status is terminated. This product is registered under clinical trial identifier NCT03203447. Target conditions include Macular Edema, Retinal Vein Occlusion.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03203447Phase 3Terminated

Competing Products

20 competing products in Macular Edema

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
44
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
4 mg CLS-TA + Sham + IVT afliberceptClearside BiomedicalPhase 2
44
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
Eylea + ALT-L9AlteogenPhase 1
33
KVD001 InjectionKalVista PharmaceuticalsPhase 2
47
KVD001 InjectionKalVista PharmaceuticalsPhase 1
28
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
77
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
77
UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
UBX1325Unity BiotechnologyPhase 2
44
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
44
UBX1325Unity BiotechnologyPhase 1
25
CT-P42 + EyleaCelltrionPhase 3
77
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
77
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
77
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Fovistaยฎ + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
52
MA09-hRPEAstellas PharmaPre-clinical
23
volociximabAstellas PharmaPhase 1
33

Other Products from Clearside Biomedical

4 mg CLS-TA Suprachoriodal InjectionPhase 3
69
4mg CLS-TA Suprachoriodal Injection + Sham ProcedurePhase 3
69
suprachoroidal CLS-TA + suprachoroidal sham + IVT afliberceptPhase 3
69
4 mg CLS-TA + Sham + IVT afliberceptPhase 2
44
CLS-AX + AfliberceptPhase 2
44